Agradecimentos: The study received financial support from the Governo Brasil agencies FAPESP #12/04565-0 and 2016/17404-5, #2013/12109-7, #2012/24667-1 (Fundação de Amparo à Pesquisa do Estado de São Paulo), CNPq (Comissão Nacional de Pesquisa) and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior). The sponsors were not involved in study design, data analysis or interpretation, writing of the manuscript, or decision to publish. Funding information Fundação de Amparo à Pesquisa do Estado de São Paulo, Grant/Award Numbers: 12/04565-0, 2012/24667-1, 2013/12109-7, 2016/17404-5 Ver menos

Abstract: Characterization of partial remission using the insulin dose-adjusted HbA1c (IDAA1c)?=?9 definition in a multiethnic Brazilian population of children and adolescents with type 1 diabetes (T1D), in addition with the determination of both Class II HLA genotype and autoantibodies. We analyzed the prevalence of partial remission in 51 new-onset T1D patients with a median time follow-up of 13 months from diagnosis. For this study, anti-GAD65, anti-IA2 and HLA class II genotyping were considered. Partial remission occurred in 41.2% of T1D patients until 3?months after diagnosis, mainly in those aged 5-15?years. We have demonstrated a significant increase in the haplotypes of class II HLA DRB1*0301-DQB1*0201 in children and adolescents with a partial remission phase of the disease (42.9% vs 21.7% in non-remitters, P = .0291). This haplotype was also associated with the reduction of anti-IA2 antibodies production. Homozygote DRB1*03-DQB1*0201/DRB1*03-DQB1*0201 children had the lowest prevalence of IA-2A antibodies (P = .0402). However, this association does not correlate with the time of the remission phase. Although the number of patients studied was reduced, our data suggested that the association between genetics and decrease in antibody production to certain islet auto-antigen may contribute, at least in part, to the remission phase of T1D Ver menos